

## The cyanobacterial lectin, microvirin-N, enhances the specificity and sensitivity of lipoarabinomannan-based TB diagnostics

Megan van der Horst<sup>#1</sup>, Leshern Karamchand<sup>#2</sup>, Westley S. Bauer<sup>#1</sup>, Andrew J.M. Nel<sup>2</sup>,  
Jonathan M. Blackburn<sup>\*2</sup>, David W. Wright<sup>\*1</sup>

<sup>1</sup> Department of Chemistry, Vanderbilt University, Station B 351822, Nashville, TN,  
37235, USA  
Fax: 615-343-1234  
Tel: 615-322-2636

<sup>2</sup> University of Cape Town, UCT Faculty of Health Sciences, Institute of Infectious  
Disease and Molecular Medicine; Department of Integrative Biomedical Sciences, Anzio  
Road, Observatory, 7925, South Africa

\*Email address: [david.wright@vanderbilt.edu](mailto:david.wright@vanderbilt.edu)


\*Email address: [jonathan.blackburn@uct.ac.za](mailto:jonathan.blackburn@uct.ac.za)

#Authors contributed equally to this work


### Table of Contents

Figure S1. MVN expression workflow.....	S-2
Figure S2. Polyacrylamide gel of IMAC fractions.....	S-3
Figure S3. Polyacrylamide gel of pooled fractions.....	S-4
Table S1. Kinetic binding analysis of pooled fractions.....	S-5
Figure S4. OB-ELISA workflow.....	S-6
Figure S5. OB-ELISA development.....	S-7
Figure S6. Antibody-based ELISA.....	S-8
Figure S7. ManLAM and PILAM titration curves on Alere LFA.....	S-9


**Figure S1.** Workflow of MVN expression protocol. **(1)** Transfection of *E. coli* BL21-DE3 competent cells with pET15b vector (ampicillin resistance gene) expressing microvirin lectin with an N-terminal hexa-histidine tag (MVN-His<sub>6</sub>); **(2)** Inoculation of 1 L Terrific Broth culture medium with overnight starter culture of MVN-His<sub>6</sub>-expressing *E. coli* BS21-DE3 cells followed by incubation of the bulk culture with ampicillin (100 µg/mL) at 37°C, 22 rpm until OD<sub>600</sub> ~0.6-0.8 was reached; **(3)** Cooling of the bulk culture to 18°C, addition of IPTG (1 mM, final concentration), and further overnight incubation (16–18 hrs) of the culture at 18 °C, 22 rpm; **(4)** Harvesting of the MVN-His<sub>6</sub>-expressing bacteria by centrifugation; **(5)** Resuspension of the bacterial pellet in lysis buffer, and lysis of bacteria by passage through an Emulsiflex-C3 High Pressure Homogenizer (Avestin) maintaining lysis pressure at 15,000 psi (three cycles), followed by clarification of the lysate by centrifugation and passage through 0.22 µm syringe filter; **(6)** Purification of MVN-His<sub>6</sub> by FPLC using a 5 mL HisTrap HP column and elution of fractions with a linear imidazole gradient (0–500 mM); **(7)** Fractions containing purified MVN-His<sub>6</sub> were pooled and dialyzed against PBS and either used fresh or stored frozen at -80 °C.



**Figure S2.** NuPAGE 4-12% gradient gels of the FPLC purification of MVN-His<sub>6</sub> from *E. coli* BL21-DE3 lysate depicting (i) molecular weight marker (gels 1 & 2, lane 1), (ii) lysate of MVN-His<sub>6</sub>-expressing *E. coli* BL21-DE3 cells (gel 1, lane 2), (iii) Flow-through from HisTrap HP column (gel 1, lane 3), and (iii) IMAC column fractions (gel 1, lanes 4-15 and continued onto gel 2, lanes 2-15). MVN-His<sub>6</sub> appears as a prominent band at a molecular weight of ~15 kDa in the cell lysate (gel 1, lane 2), but is largely absent in the flow-through (gel 1, lane 3), which indicates the successful binding of MVN-His<sub>6</sub> to the Ni-NTA HisTrap column. Elution of MVN-His<sub>6</sub> under the linear imidazole gradient peaked around the 10<sup>th</sup> fraction (gel 1, lane 13) and subsequently tapered off as observed by changing intensities of the dark bands at a molecular weight of ~15 kDa. The elution fractions were pooled as follows for further analysis; **Pool 1:** gel 1, lanes 6-9; **Pool 2:** gel 1, lanes 10-13; **Pool 3:** gel 1, lanes 14-15 and gel 2, lanes 2-6; **Pool 4:** gel 2, lanes 7-10. 10  $\mu$ L aliquots of each 2 mL fraction was loaded per well.




**Figure S3.** NuPAGE 4-12% gradient gel of pooled FPLC elution fractions. **(A)** Pools 2 and 3 were diluted ten-fold prior to being loaded onto the gel. **(B)** Pools 1 and 4 were loaded undiluted onto the gel. All pools were loaded in three lanes with 2.5, 5, and 10  $\mu$ L sample, left to right. BSA standards (100, 250, 500, 750, and 1000 ng) were also loaded onto the gel to enable densitometric quantification of MVN-His<sub>6</sub> in the various elution fractions.




**Table S1.** Kinetic binding analysis of pooled fractions containing MVN-His<sub>6</sub> to *M.tb* H37Rv ManLAM. The combined fraction Pools 2 and 3 exhibited higher binding affinity toward *M.tb* H37Rv ManLAM and higher purity compared to Pools 1 and 4 (Figure S3). Therefore, fraction Pools 2 and 3 were combined, and used exclusively for further assay development.

<b>Fraction</b>	<b>Binding Affinity (K<sub>D</sub>) to ManLAM</b>
1	Not tested
2	1.18 nM
3	61.3 pM
4	0.487 nM


**Figure S4.** 100  $\mu\text{L}$  of ManLAM or PILAM in pooled human urine is added to a clear flat-bottom 96-well plate. A 100  $\mu\text{L}$  aliquot of 2  $\mu\text{g}/\text{mL}$  Ab28 conjugated to HRP in 0.5% BSA PBST is then added to the wells. Lastly, 4  $\mu\text{L}$  MVN-functionalized magnetic Dynabeads is added to each well and the plate is incubated on a shaker for 30 minutes. The beads are magnetically separated from the supernatant using a 96-well magnetic separation rack and washed three times with 200  $\mu\text{L}$  PBST. A 100  $\mu\text{L}$  aliquot of TMB One is then added to each well and the plate is incubated on a shaker for 10 minutes while protected from light. Lastly, 100  $\mu\text{L}$  2 M  $\text{H}_2\text{SO}_4$  is added to each well to stop the reaction and the signal was measured by absorbance at 450 nm.



**Figure S5.** Development of the OB-ELISA. **(A)** Signal-to-noise ratios for sequential addition vs all-in-one addition format for OB-ELISA showing no significant different (p-value = 0.21). **(B)** Optimization of detection antibody concentration. **(C)** Optimization of bead number and type where Bead 1 was functionalized with 60  $\mu\text{g}$  MVN per 100  $\mu\text{L}$  beads and Bead 2 was functionalized with 30  $\mu\text{g}$  MVN per 100  $\mu\text{L}$  beads.



**Figure S6.** An antibody-based ELISA was developed. **(A)** The concentration of capture antibody Ab170 was optimized and 4  $\mu\text{g}/\text{mL}$  was chosen. **(B)** The percentage of BSA in the blocking buffer was optimized and 1.25% was chosen. **(C)** The concentration of detection antibody Ab28 conjugated to HRPx was optimized and 0.5  $\mu\text{g}/\text{mL}$  was chosen. **(D)** Standard curves of ManLAM and PILAM spiked into urine were used to determine the LODs of 729  $\text{pg}/\text{mL}$  and 360  $\text{pg}/\text{mL}$ , respectively.





**Figure S7.** Titration curves of *M. tb* ManLAM or *M. smegmatis* PILAM on the Alere LFA. The visual LODs were found to be 1.25 ng/mL ManLAM and 0.625 ng/mL PILAM.

